Table 3 Studying the independent effect of higher vs. lower sADO levels in mature B-cell lymphoma patients.
From: Illuminating the impact of CD38-induced adenosine formation in B-cell lymphoma
Mature B-cell lymphoma | sADO < 694 ng/ml | sADO ≥ 694 ng/ml | P-value | |
|---|---|---|---|---|
No. = 44 | No. = 46 | |||
Age(years) | Mean ± SD | 56.23 ± 10.13 | 54.93 ± 18.52 | 0.684• |
Range | 23–69 | 23–80 | ||
Sex | Females | 13 (29.5%) | 12 (26.1%) | 0.714 |
Males | 31 (70.5%) | 34 (73.9%) | ||
WBC(x 103/ul) | Median (IQR) | 58 (27.3–112.5) | 50 (15.4–70) | 0.248≠ |
Range | 3.5–831 | 3.01–589 | ||
LYMPH(x 103/ul) | Median (IQR) | 48 (19.5–96.5) | 32.5 (15–58) | 0.218≠ |
Range | 2.4–165 | 2–538 | ||
HB(g/dl) | Mean ± SD | 10.32 ± 2.84 | 9.13 ± 2.27 | 0.031• |
Range | 4.2–16.1 | 4.2–14 | ||
PLT(x 103/ul) | Median (IQR) | 157 (86.5–258) | 100 (50–142) | 0.002≠ |
Range | 16–402 | 10–576 | ||
BM.LYM(%) | Mean ± SD | 74.61 ± 18.1 | 74.3 ± 20.73 | 0.940• |
Range | 21–95 | 10–98 | ||
P53 deletion | Negative | 10 (83.3%) | 5 (41.7%) | 0.035* |
Positive | 2 (16.7%) | 7 (58.3%) | ||
CD38 degree | Median (IQR) | 4.5 (1–8) | 58 (41–87) | 0.000≠ |
Range | 0–99 | 0.1–100 | ||
sPD-L1(ng/L) | Median (IQR) | 126.2 (70.91–395.15) | 173.98 (140.6–391.2) | 0.017≠ |
Range | 21.51–1427 | 50–1600 | ||
sPD-1(ng/L) | Median (IQR) | 99.34 (54–153.5) | 197 (148–312) | 0.000≠ |
Range | 19.38–1070 | 37–1300 | ||
Risk stratification | Low | 15 (34.1%) | 7 (15.2%) | 0.088* |
Intermediate | 16 (36.4%) | 18 (39.1%) | ||
High | 13 (29.5%) | 21 (45.7%) | ||
